← All I-mab filings

I-mab 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

IMAB
I-mab
20-F/A: NovaBridge Biosciences Files 20-F/A Ownership Correction
NovaBridge Biosciences has filed an amendment to its 2025 annual report to correct inadvertent errors in previously reported beneficial ownership information.
IMAB
I-mab
20-F: NovaBridge Biosciences Amends Collaboration Agreement
NovaBridge Biosciences and I-MAB Biopharma US Limited have entered into Amendment Eight to their Collaboration Agreement, effective November 2, 2025, modifying terms related to development cost sharing and regulatory control.
IMAB
I-mab
20-F: I-Mab Announces Fiscal Year 2024 Results, Strategic Realignment
I-Mab reports its 2024 financial results and details a strategic realignment focusing on its lead program, givastomig, while reducing workforce by 27%.
IMAB
I-mab
20-F: I-Mab Reports Fiscal Year 2023 Results, Divests Greater China Assets
I-Mab reports its 2023 financial results and finalizes the divestiture of its Greater China assets to focus on its global pipeline.